Status:
TERMINATED
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Genentech, Inc.
Eli Lilly and Company
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung canc...
Detailed Description
The patients on this study will receive treatment in 3 stages of therapy. The first stage is Induction Therapy. This therapy is 7 weeks long. Patients will receive bevacizumab followed by pemetrexed ...
Eligibility Criteria
Inclusion
- Clinically confirmed non-small cell lung cancer stage IIIA and selected stage IIIB
- Measurable or evaluable disease
- Be up and about and able to care for self
- Adequate kidney, liver and bone marrow function
- No prior treatment for this disease
- Must be able to give written informed consent
- Must be able to take folic acid, vitamin B12 and dexamethasone as described in the protocol
- Age 18 years or older
Exclusion
- Stage IV or IIIB patients with pleural or pericardial effusions
- Stage IIIB disease with contralateral mediastinal nodes greater than 4cm
- Squamous cell predominant tumors
- Pregnant or lactating women
- Patients with active infections
- History of another cancer within the last 5 years with the exception of skin cancer or cervical carcinoma in situ
- History of stroke, transient ischemic attacks, or acute MI within the past 6 months or any other serious cardiovascular disease
- Symptoms of peripheral vascular disease
- History of neurological disease
- Recent history of blood in the sputum or vomitus
- Non-healing wounds, ulcer or long bone fractures
- History of bleeding problems or coagulation problems
- History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 6 months
- History of uncontrolled hypertension
- Chronic use of non-steroidal anti-inflammatory medication not allowed on this study
- Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00402883
Start Date
November 1 2006
End Date
January 1 2009
Last Update
November 9 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Gainsville Hematology Oncology Associates
Gainesville, Florida, United States, 32605
2
Watson Clinic Center for Cancer Care and Research
Lakeland, Florida, United States, 33805
3
Wellstar Cancer Research
Marietta, Georgia, United States, 30060
4
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States, 40207